INDICATIONS FOR CYLTEZO® (adalimumab-adbm) INJECTION, FOR SUBCUTANEOUS USE This important information also applies to Adalimumab-adbm injection for subcutaneous use. Rheumatoid Arthritis: CYLTEZO is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression...
Adalimumab-adbm injection is also used to treat moderate to severe chronic plaque psoriasis, which is a skin disease with red patches and white scales that do not go away. It is given to patients who may receive other types of treatment, including pills, injection, or phototherapy (light tre...
Hepatitis B infection in carriers of the virus.Symptoms include muscle aches, feeling very tired, dark urine, skin or eyes that look yellow, little or no appetite, vomiting, clay-colored bowel movements, fever, chills, stomach discomfort, and skin rash. ...
showed no between-group differences by age and sex.CONCLUSIONSIn patients with RA, CD, and PsO, there were no differences between biosimilar adalimumab-adbm or the adalimumab RP regarding the rate of AEs, SAEs, discontinuations due to AEs, deaths, or any AEs of special interest....
In adalimumab clinical trials, there was an approximate 3-fold higher rate of lymphoma than expected in the general U.S. population. Patients with chronic inflammatory diseases, particularly those with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at higher risk...
adalimumab biosimilar 基本信息 药品名称 adalimumab-adbm; Cyltezo; BI 695501 药品类别 生物类似药; 生物; 抗体 靶点 tumor necrosis factor alpha (TNF-α) 作用机制 anti-TNF-α单抗 药品简介 -- 研发机构 Boehringer Ingelheim 最高研发阶段 全球: 批准上市 中国: 临床前 美国: 批准上市 欧洲: ...
In adalimumab clinical trials, there was an approximate 3-fold higher rate of lymphoma than expected in the general U.S. population. Patients with chronic inflammatory diseases, particularly those with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at higher risk...
and we recognize the critical need for ensuring biosimilars are affordable to all,” Dorothy Gemmell, chief commercial officer at GoodRx, stated.1“We’re excited to leverage the reach and scale of the GoodRx platform to help address this access gap and make Adalimumab-adbm more acces...
Participants who were given the high-concentration formulation of adalimumab-adbm experienced a lower incidence of adverse events and local reactions than those who were given the reference formulation.Conclusions Overall, the high-concentration and reference adalimumab-adbm formulations had highly similar ...
Adalimumab-adbm (Cyltezo®, formerly known as BI 695501; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany) is an approved interchangeable biosimilar to adalimumab reference product (Humira®; AbbVie Inc., North Chicago, IL, USA) in the USA [9, 10]. Adalimumab-adbm and...